Safety and Tolerability of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

Phase 3 Completed 836 enrolled Takeda H. Lundbeck A/S · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the long-term efficacy and safety of vortioxetine, once daily (QD), in adults with major depressive disorder.

Timeline

Start: 2008-06
Primary completion: 2010-07
Completion: 2010-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Vortioxetine	Unknown	2.5 mg	Oral
Subject	Vortioxetine	Unknown	5 mg	Oral
Subject	Vortioxetine	Unknown	10 mg	Oral

Safety and Tolerability of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

Summary

Timeline

Drugs

Indications